Short Interest in InflaRx N.V. (NASDAQ:IFRX) Rises By 203.1%

InflaRx N.V. (NASDAQ:IFRX) was the target of a significant increase in short interest in the month of May. As of May 15th, there was short interest totaling 6,039,577 shares, an increase of 203.1% from the April 30th total of 1,992,416 shares. Currently, 10.0% of the company’s stock are short sold. Based on an average daily volume of 4,655,170 shares, the days-to-cover ratio is presently 1.3 days.

Analysts Set New Price Targets

A number of analysts have issued reports on IFRX shares. Oppenheimer started coverage on shares of InflaRx in a research note on Friday, April 24th. They issued an “outperform” rating and a $5.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research note on Friday, March 27th. Guggenheim reiterated a “buy” rating and issued a $14.00 target price on shares of InflaRx in a research note on Tuesday, April 21st. Cantor Fitzgerald lifted their target price on shares of InflaRx from $2.00 to $4.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Finally, Raymond James Financial upgraded shares of InflaRx from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $7.00 to $9.00 in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Hedge Funds Weigh In On InflaRx

Institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC raised its position in shares of InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares during the period. HRT Financial LP bought a new position in shares of InflaRx in the fourth quarter valued at approximately $47,000. Concurrent Investment Advisors LLC raised its position in shares of InflaRx by 56.9% in the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after purchasing an additional 19,200 shares during the period. Insigneo Advisory Services LLC bought a new position in shares of InflaRx in the fourth quarter valued at approximately $61,000. Finally, Quadrature Capital Ltd bought a new position in shares of InflaRx in the fourth quarter valued at approximately $104,000. Institutional investors own 42.39% of the company’s stock.

InflaRx Stock Up 0.8%

NASDAQ IFRX opened at $2.40 on Friday. InflaRx has a 12-month low of $0.74 and a 12-month high of $2.95. The stock has a market capitalization of $173.50 million, a PE ratio of -3.38 and a beta of 2.42. The company has a 50 day moving average price of $1.69 and a two-hundred day moving average price of $1.26.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. As a group, equities analysts anticipate that InflaRx will post -0.51 EPS for the current year.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.